Protein 1 | Protein 2 | Combine Score |
---|---|---|
HIF1A | EGLN1 | 0.999 |
EGLN1 | EPAS1 | 0.997 |
EGLN2 | HIF1A | 0.995 |
EGLN2 | EPAS1 | 0.994 |
HIF1A | EGLN3 | 0.991 |
EPAS1 | EGLN3 | 0.983 |
HIF3A | EGLN3 | 0.976 |
EGLN2 | HIF3A | 0.975 |
EGLN1 | OS9 | 0.974 |
HIF3A | EGLN1 | 0.973 |
HIF1A | OS9 | 0.966 |
OS9 | EGLN3 | 0.952 |
HIF3A | EPAS1 | 0.94 |
HIF1A | HIF3A | 0.939 |
EGLN1 | EGLN3 | 0.931 |
EGLN2 | EGLN3 | 0.931 |
EGLN2 | OS9 | 0.927 |
HIF1A | EPAS1 | 0.916 |
EGLN2 | EGLN1 | 0.907 |
# | 3091 (HIF1A) | 54583 (EGLN1) | 112398 (EGLN2) | 2034 (EPAS1) | 64344 (HIF3A) | 10956 (OS9) | 112399 (EGLN3) |
---|---|---|---|---|---|---|---|
3091 (HIF1A) | 1.00 | 0.57 | 0.54 | 0.89 | 1.00 | 1.00 | 0.56 |
54583 (EGLN1) | 0.57 | 1.00 | 0.93 | 0.53 | 0.21 | 1.00 | 0.89 |
112398 (EGLN2) | 0.54 | 0.93 | 1.00 | 0.51 | 0.21 | 1.00 | 0.85 |
2034 (EPAS1) | 0.89 | 0.53 | 0.51 | 1.00 | 1.00 | 1.00 | 0.54 |
64344 (HIF3A) | 1.00 | 0.21 | 0.21 | 1.00 | 1.00 | 0.21 | 0.21 |
10956 (OS9) | 1.00 | 1.00 | 1.00 | 1.00 | 0.21 | 1.00 | 1.00 |
112399 (EGLN3) | 0.56 | 0.89 | 0.85 | 0.54 | 0.21 | 1.00 | 1.00 |
Protein Official symbol | Source Organism | Tissue of Expression | Level of hypoxia | Altitude | Duration of experiment | Level of expression | Fold change | Experiment details | geographical location | ethnicity of the patients | Control group | Control (Fold change) | Reference (PMID) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EGLN2 | Mice | Blood | 8% Oxygen | 7600 m | 24 hours | upregulated | 11.3 | RT-qPCR | Western US | C57BL/6 mice | 1.4 | 7600m mice(8% oxygen with Fenofibrate injections Vs Baseline normoxia mice (21% oxygen) | 24183776 |
EGLN2 | Mice | Blood | 8% Oxygen | 7600 m | 24 hours | upregulated | 8.5 | RT-qPCR | Western US | C57BL/6 mice | 1.4 | 7600m mice(8% oxygen with no Fenofibrate injections Vs Baseline normoxia mice (21% oxygen) | 24183776 |
miRTarBase ID | miRNA | Species (miRNA) | Protein Official Symbol | Human Entrez ID | Species (Target Gene) | Experiments | Support Type | References (PMID) |
---|---|---|---|---|---|---|---|---|
MIRT006784 | hsa-miR-205-5p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | Luciferase reporter assay//Microarray//qRT-PCR//Western blot | Functional MTI | 22859986 |
MIRT049430 | hsa-miR-92a-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT051206 | hsa-miR-16-5p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT708268 | hsa-miR-6829-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708265 | hsa-miR-6836-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708267 | hsa-miR-7977 | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708273 | hsa-miR-4267 | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708270 | hsa-miR-6778-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708266 | hsa-miR-6749-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708269 | hsa-miR-6791-3p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708272 | hsa-miR-5193 | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
MIRT708271 | hsa-miR-136-5p | Homo sapiens | EGLN2 | 112398 | Homo sapiens | HITS-CLIP | Functional MTI (Weak) | 19536157 |
ID | GO ID | GO Term | GO Type |
---|---|---|---|
112398 | GO:0016705 | oxidoreductase activity | GOTERM_MF_DIRECT |
112398 | GO:0031418 | carboxylic acid binding | GOTERM_MF_DIRECT |
112398 | GO:0016491 | oxidoreductase activity | GOTERM_MF_DIRECT |
112398 | GO:0019826 | oxygen binding | GOTERM_MF_DIRECT |
112398 | GO:0043523 | regulation of neuron apoptotic process | GOTERM_BP_DIRECT |
112398 | GO:0045454 | cell redox homeostasis | GOTERM_BP_DIRECT |
112398 | GO:0001666 | response to hypoxia | GOTERM_BP_DIRECT |
112398 | GO:0005634 | nucleus | GOTERM_CC_DIRECT |
112398 | GO:0005654 | nucleoplasm | GOTERM_CC_DIRECT |
112398 | GO:0018401 | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | GOTERM_BP_DIRECT |
112398 | GO:0045732 | positive regulation of protein catabolic process | GOTERM_BP_DIRECT |
112398 | GO:0030520 | intracellular estrogen receptor signaling pathway | GOTERM_BP_DIRECT |
112398 | GO:0016706 | oxidoreductase activity | GOTERM_MF_DIRECT |
112398 | GO:0055114 | oxidation-reduction process | GOTERM_BP_DIRECT |
112398 | GO:0061418 | regulation of transcription from RNA polymerase II promoter in response to hypoxia | GOTERM_BP_DIRECT |
112398 | GO:0005506 | iron ion binding | GOTERM_MF_DIRECT |
112398 | GO:0008198 | phosphatidate phosphatase activity | GOTERM_MF_DIRECT |
112398 | GO:0001558 | regulation of cell growth | GOTERM_BP_DIRECT |
112398 | GO:0005515 | protein binding | GOTERM_MF_DIRECT |
112398 | GO:0031545 | thyrotropin-releasing hormone receptor binding | GOTERM_MF_DIRECT |
Protein Official Symbol | Human Entrez ID | Disease Name | Disease Id | Disease Semantic Type | Semantic score | DSI | DPI | Disease Type |
---|---|---|---|---|---|---|---|---|
EGLN2 | 112398 | Malignant neoplasm of aortic body and other paraganglia | C0438413 | Neoplastic Process | 0.3 | 0.624 | 0.586 | disease |
EGLN2 | 112398 | Benign neoplasm of aortic body and other paraganglia | C0154045 | Neoplastic Process | 0.3 | 0.624 | 0.586 | disease |
EGLN2 | 112398 | Benign neoplasm of adrenal gland | C0154040 | Neoplastic Process | 0.3 | 0.624 | 0.586 | disease |
EGLN2 | 112398 | Malignant Adrenal Medulla Neoplasm | C0344456 | Neoplastic Process | 0.3 | 0.624 | 0.586 | disease |
EGLN2 | 112398 | TOBACCO ADDICTION, SUSCEPTIBILITY TO (finding) | C1861063 | Finding | 0.3 | 0.624 | 0.586 | phenotype |
EGLN2 | 112398 | Familial erythrocytosis | C0152264 | Disease or Syndrome | 0.3 | 0.624 | 0.586 | disease |
Protein Official Symbol | Human Entrez ID | drug_claim_primary_name | drug_name | drug_chembl_id | interaction_types |
---|---|---|---|---|---|
EGLN2 | 112398 | AKB-6548 | VADADUSTAT | CHEMBL3646221 | None |
EGLN2 | 112398 | COMPOUND 6EE [PMID: 22364528] | None | None | inhibitor |
EGLN2 | 112398 | DAPRODUSTAT | DAPRODUSTAT | CHEMBL3544988 | inhibitor |
EGLN2 | 112398 | FG-2216 | CHEMBL426560 | CHEMBL426560 | inhibitor |
EGLN2 | 112398 | FG-4592 | ROXADUSTAT | CHEMBL2338329 | None |
EGLN2 | 112398 | FG-2216 | CHEMBL426560 | CHEMBL426560 | None |
EGLN2 | 112398 | FG-4592 | ROXADUSTAT | CHEMBL2338329 | inhibitor |
EGLN2 | 112398 | GSK1278863 | DAPRODUSTAT | CHEMBL3544988 | inhibitor |
EGLN2 | 112398 | ROXADUSTAT | ROXADUSTAT | CHEMBL2338329 | inhibitor |